| Peer-Reviewed

Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report

Received: 28 February 2015     Accepted: 4 March 2015     Published: 23 June 2015
Views:       Downloads:
Abstract

This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA.

Published in American Journal of Internal Medicine (Volume 3, Issue 4)
DOI 10.11648/j.ajim.20150304.12
Page(s) 156-159
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2015. Published by Science Publishing Group

Keywords

Autoimmune Hemolytic Anemia, Rituximab, Mixed Autoimmune Hemolytic Anemia

References
[1] S. Bluml, K. McKeever, R. Ettinger, J. Smolen and R. Herbst. B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013; 15 Suppl 1: S4.
[2] K. Lechner and U. Jager. How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116(11): 1831-8.
[3] G. Bussone, E. Ribeiro, A. Dechartres, J. F. Viallard, B. Bonnotte, O. Fain, B. Godeau and M. Michel. Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009; 84(3): 153-7.
[4] S. Berentsen, E. Ulvestad, B. T. Gjertsen, H. Hjorth-Hansen, R. Langholm, H. Knutsen, W. Ghanima, F. V. Shammas and G. E. Tjonnfjord. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8): 2925-8.
[5] C. E. Brown, J. P. Traynor, R. A. Sharp and J. G. Fox. Successful treatment with rituximab of autoimmune haemolytic anaemia causing dialysis-dependent acute renal failure. Nephrol Dial Transplant. 2007; 22(9): 2730-1.
[6] D. Webster, B. Ritchie and M. J. Mant. Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies. Am J Hematol. 2004; 75(4): 258-9.
[7] K. Ono, T. Sato, S. Iyama, A. Tatekoshi, A. Hashimoto, Y. Kamihara, H. Horiguchi, S. Kikuchi, K. Takada, T. Hayashi, K. Miyanishi, Y. Sato, R. Takimoto, M. Kobune and J. Kato. Successful treatment with rituximab in a patient with refractory mixed-type autoimmune hemolytic anemia [Japanese article]. Rinsho Ketsueki. 2013; 54(11): 2053-5.
[8] S. Gupta, A. Szerszen, F. Nakhl, S. Varma, A. Gottesman, F. Forte and M. Dhar. Severe refractory autoimmune hemolytic anemia with both warm and cold autoantibodies that responded completely to a single cycle of rituximab: a case report. J Med Case Rep. 2011; 5: 156.
[9] M. Morselli, M. Luppi, L. Potenza, S. Tonelli, D. Dini, G. Leonardi, A. Donelli, F. Narni and G. Torelli. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood. 2002; 99(9): 3478-9.
Cite This Article
  • APA Style

    Motoharu Shibusawa, Yoshirou Murai, Hisashi Tsutsumi. (2015). Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. American Journal of Internal Medicine, 3(4), 156-159. https://doi.org/10.11648/j.ajim.20150304.12

    Copy | Download

    ACS Style

    Motoharu Shibusawa; Yoshirou Murai; Hisashi Tsutsumi. Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. Am. J. Intern. Med. 2015, 3(4), 156-159. doi: 10.11648/j.ajim.20150304.12

    Copy | Download

    AMA Style

    Motoharu Shibusawa, Yoshirou Murai, Hisashi Tsutsumi. Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report. Am J Intern Med. 2015;3(4):156-159. doi: 10.11648/j.ajim.20150304.12

    Copy | Download

  • @article{10.11648/j.ajim.20150304.12,
      author = {Motoharu Shibusawa and Yoshirou Murai and Hisashi Tsutsumi},
      title = {Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report},
      journal = {American Journal of Internal Medicine},
      volume = {3},
      number = {4},
      pages = {156-159},
      doi = {10.11648/j.ajim.20150304.12},
      url = {https://doi.org/10.11648/j.ajim.20150304.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20150304.12},
      abstract = {This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA.},
     year = {2015}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Successful Rituximab Treatment of Autoimmune Hemolytic Anemia Caused by Both Warm Autoantibodies and Cold Agglutinin: A Case Report
    AU  - Motoharu Shibusawa
    AU  - Yoshirou Murai
    AU  - Hisashi Tsutsumi
    Y1  - 2015/06/23
    PY  - 2015
    N1  - https://doi.org/10.11648/j.ajim.20150304.12
    DO  - 10.11648/j.ajim.20150304.12
    T2  - American Journal of Internal Medicine
    JF  - American Journal of Internal Medicine
    JO  - American Journal of Internal Medicine
    SP  - 156
    EP  - 159
    PB  - Science Publishing Group
    SN  - 2330-4324
    UR  - https://doi.org/10.11648/j.ajim.20150304.12
    AB  - This report describes a case which successfully treated with rituximab against autoimmune hemolytic anemia caused by both warm autoantibodies and cold agglutinin (mixed AIHA). A 52-year-old man with malaise was referred to our hospital in December 2002. A diagnosis of mixed AIHA was made. His clinical course showed that the hemolysis was mainly caused by cold agglutinin, with a possible contribution from the warm autoantibody. He was treated with prednisolone (PSL), Cyclosporine (CyA), and cyclophosphamide (CPA). The treatment with PSL, CyA, and CPA failed to stabilize the hemolysis caused by cold exposure in the winter season. In November 2013 (winter season), rituximab therapy (375 mg/m2 weekly for four weeks) was started, and the hemolysis improved. The present case suggests that rituximab is useful against mixed AIHA. Further studies are warranted to establish the effectiveness of rituximab against mixed AIHA.
    VL  - 3
    IS  - 4
    ER  - 

    Copy | Download

Author Information
  • Department of Hematology Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation, Tama-Hokubu Medical Center, Tokyo, Japan

  • Department of Hematology Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation, Tama-Hokubu Medical Center, Tokyo, Japan

  • Department of Hematology Medicine, Tokyo Metropolitan Health and Medical Treatment Corporation, Tama-Hokubu Medical Center, Tokyo, Japan

  • Sections